Ligand Pharmaceuticals LGND Capvaxive — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's capvaxive — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's capvaxive — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported capvaxive — total revenues and income of $1.97M in Q1 2026.
- How has Ligand Pharmaceuticals's capvaxive — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's capvaxive — total revenues and income increased by 122.5% year-over-year, from $885K to $1.97M.
- What does capvaxive — total revenues and income mean?
- This metric represents the aggregate financial inflows generated by the Capvaxive product line, including royalties, milestone payments, and license fees. It serves as a key indicator of the commercial adoption and market performance of this specific therapeutic asset within the company's portfolio. Tracking this revenue stream allows investors to evaluate the direct contribution of the product to the company's overall top-line growth and long-term value creation.